CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Cash flows from operating activities:
Net loss	$ (153,266,286)	$ (59,135,716)	$ (48,123,971)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of warrant liabilities	61,073,808
Warrant related expense	7,649,395
Depreciation and amortization	923,348	737,661	578,066
Amortization of deferred revenue	(79,292)	(202,088)	(5,712)
Amortization of bond premiums	218,426	669,858	544,208
Amortization of debt issuance costs	729,821	729,821	281,791
Amortization of deferred rent	8,996	99,516	99,516
Loss (gain) on sale of marketable securities	15,682	(1,844)	(11,015)
(Decrease) increase in allowance for doubtful accounts	(61,932)	20,369	(34,432)
Non-cash expense related to stock compensation	4,333,430	3,740,526	2,788,677
Non-cash decrease in value of life insurance policy		20,566	155,544
Non-cash financing expenses	346,568
Changes in operating assets and liabilities
Accounts receivable	102,640	(190,300)	271,820
Inventory	(195,958)	256,381	328,126
Other receivables	223,340	620,300	(553,966)
Prepaid expenses	146,871	97,948	478,794
Other current assets	(241,775)	761,803	(776,975)
Accounts payable and accrued expenses	15,807,887	3,147,606	4,946,099
Deferred revenues	14,887	165,793	37,221
Net cash used in operating activities	(62,250,144)	(48,461,800)	(38,996,209)
Cash flows from investing activities:
Purchases of marketable securities	(131,610,011)	(2,749,117)	(86,307,071)
Proceeds from sales/maturities of marketable securities	57,183,499	50,850,088	34,491,153
Purchases of property and equipment	(1,837,167)	(2,226,256)	(924,429)
Net cash (used in) provided by investing activities	(76,263,679)	45,874,715	(52,740,347)
Cash flows from financing activities:
Sale of preferred stock, net of related expenses	121,781,941
Proceeds from public offering of common stock, net of expenses	28,578,473
Proceeds from sale of common stock to Seattle Genetics, Inc.	14,700,000
Proceeds from issuance of convertible senior notes			100,000,000
Payment of debt issuance costs			(3,657,215)
Exercise of stock options	4,290,103	2,732,962	2,959,930
Tax withholding payments for stock compensation	(547,021)	(368,984)	(585,725)
Net cash provided by financing activities	168,803,496	2,363,978	98,716,990
Effect of changes in exchange rates on cash and cash equivalents	(99,728)	(26,043)	(489,153)
Net increase (decrease) in cash and cash equivalents	30,189,945	(249,150)	6,491,281
Cash and cash equivalents beginning of the year	13,203,625	13,452,775	6,961,494
Cash and cash equivalents end of the year	43,393,570	13,203,625	13,452,775
Supplemental disclosure of cash flow information:
Interest paid	4,750,000	4,802,778
Income taxes paid	$ 23,636	$ 28,679	$ 75,598